Nathan D Seligson

Nathan D Seligson, Pharm.D.

Clinical Assistant Professor

Department: Pharmacotherapy & Translational Research
Business Phone: (904) 244-9590
Business Email: nseligson@cop.ufl.edu

About Nathan D Seligson

Dr. Seligson earned his Doctor of Pharmacy degree from the University of South Florida prior to completing a pharmacy practice residency. Dr. Seligson then completed a post-doctoral fellowship in translational hematology/oncology focused on precision medicine in sarcoma.

Dr. Seligson is a Clinical Assistant Professor in the Department of Pharmacotherapy and Translational Research. His clinical practice includes activities as a clinical pharmacogenomics specialist and hematology/oncology research scientist at Nemours Children’s Specialty Care in Jacksonville, Florida.

Dr. Seligson has been published in as first author in leading journals including: JAMA Open Network, The Oncologist, and npj Precision Medicine. His current research includes work to better understand cancer biology and tumor evolution in order to provide actionable molecular subtyping and pharmacogenomic therapy guidance in sarcoma.

Research Profile

Open Researcher and Contributor ID (ORCID)

0000-0002-9670-3792

Publications

2021
Adding the second T: Elevating STAR to START for behavioral interviewing.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 78(1):18-21 [DOI] 10.1093/ajhp/zxaa356. [PMID] 33155021.
2021
Developing Drugs for Tissue-Agnostic Indications: A Paradigm Shift in Leveraging Cancer Biology for Precision Medicine.
Clinical pharmacology and therapeutics. 109(2):334-342 [DOI] 10.1002/cpt.1946. [PMID] 32535906.
2021
Evaluation of the timing of MRSA PCR nasal screening: How long can a negative assay be used to rule out MRSA-positive respiratory cultures?
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 78(Supplement_2):S57-S61 [DOI] 10.1093/ajhp/zxab109. [PMID] 33788910.
2021
Key Considerations for Selecting a Genomic Decision Support Platform for Implementing Pharmacogenomics.
Clinical pharmacology and therapeutics. 110(3):555-558 [DOI] 10.1002/cpt.2328. [PMID] 34254671.
2021
Multiscale-omic assessment of EWSR1-NFATc2 fusion positive sarcomas identifies the mTOR pathway as a potential therapeutic target.
NPJ precision oncology. 5(1) [DOI] 10.1038/s41698-021-00177-0. [PMID] 34021224.
2021
Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer
Annals of Pharmacotherapy. 55(7):921-931 [DOI] 10.1177/1060028020966548.
2021
UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation
Cancers. 13(7) [DOI] 10.3390/cancers13071566. [PMID] 33805415.
2020
Association of ANRIL Polymorphism With Overall Survival in Adult Patients With Hematologic Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation.
Anticancer research. 40(10):5707-5713 [DOI] 10.21873/anticanres.14585. [PMID] 32988896.
2020
Convergence of therapy-induced senescence (TIS) and EMT in multistep carcinogenesis: current opinions and emerging perspectives.
Cell death discovery. 6 [DOI] 10.1038/s41420-020-0286-z. [PMID] 32566256.
2020
Integration of EMT and cellular survival instincts in reprogramming of programmed cell death to anastasis.
Cancer metastasis reviews. 39(2):553-566 [DOI] 10.1007/s10555-020-09866-x. [PMID] 32020420.
2020
Recommendations for patient similarity classes: results of the AMIA 2019 workshop on defining patient similarity
Journal of the American Medical Informatics Association. 27(11):1808-1812 [DOI] 10.1093/jamia/ocaa159. [PMID] 32885823.
2019
BRCA1/2 Functional Loss Defines a Targetable Subset in Leiomyosarcoma.
The oncologist. 24(7):973-979 [DOI] 10.1634/theoncologist.2018-0448. [PMID] 30541756.
2019
Common Secondary Genomic Variants Associated With Advanced Epithelioid Hemangioendothelioma.
JAMA network open. 2(10) [DOI] 10.1001/jamanetworkopen.2019.12416. [PMID] 31577358.
2019
Degree of MDM2 Amplification Affects Clinical Outcomes in Dedifferentiated Liposarcoma.
The oncologist. 24(7):989-996 [DOI] 10.1634/theoncologist.2019-0047. [PMID] 31019022.
2019
Inhibition of histone deacetylase 2 reduces MDM2 expression and reduces tumor growth in dedifferentiated liposarcoma.
Oncotarget. 10(55):5671-5679 [DOI] 10.18632/oncotarget.27144. [PMID] 31620242.
2019
XRCC1-mediated DNA repair is associated with progression-free survival of multiple myeloma patients after autologous stem cell transplant.
Molecular carcinogenesis. 58(12):2327-2339 [DOI] 10.1002/mc.23121. [PMID] 31544312.
2018
Evaluating the Impact of the Addition of Cladribine to Standard Acute Myeloid Leukemia Induction Therapy.
The Annals of pharmacotherapy. 52(5):439-445 [DOI] 10.1177/1060028017749214. [PMID] 29241342.

Education

Post-doctoral Fellowship in Translational Hematology/Oncology
2016-2019 · The Ohio State University
PGY1 Pharmacy Practice Residency
2015-2016 · Baptist Memorial Healthcare – Memphis
Pharm.D.
2011-2015 · University of South Florida
B.S.
2007-2011 · University of Central Florida

Teaching Profile

Courses Taught
2020
PHA6136 Clinical Applications of Precision Medicine: Oncology
2021
PHA6935 Selected Topics in Pharmacy
2021
PHA5012 App Personalized Med

Contact Details

Phones:
Business:
(904) 244-9590
Emails: